Mutations associated with lamivudine-resistance in therapy-naive hepatitis B virus (HBV) infected patients with and without HIV co-infection: Implications for antiretroviral therapy in HBV and HIV co-infected south African patients

被引:43
|
作者
Selabe, S. Gloria
Lukhwareni, Azwidowi
Song, Ernest
Leeuw, Yeegan G. M.
Burnett, Rosemary J.
Mphahlele, M. Jeffrey
机构
[1] Univ Limpopo, Dept Virol, HIV & Hepatitis Res Unit, Pretoria, South Africa
[2] Johannesburg Hosp, Hepatol Div, Dept Med, Johannesburg, South Africa
[3] Univ Witwatersrand, Johannesburg, South Africa
[4] Margarita Hlth Ctr, Pretoria, South Africa
关键词
lamivudine-resistant HBV strains; hepatitis B virus; human immunodeficiency virus; HBV-HIV coinfection; sub-Saharan Africa;
D O I
10.1002/jmv.20974
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
This was an exploratory study to investigate larnivudine-resistant hepatitis 13 virus (HBV) strains in selected lamivudine-naive HBV carriers with and without human immunodeficiency virus (HIV) co-infection in South African patients. Thirty-five lamivudine-naive HBV infected patients with or without HIV co-infection were studied: 15 chronic HBV mono-infected patients and 20 HBV-HlV co-infected patients. The latter group was further sub-divided into 13 occult HBV (HBsAg-negative) and 7 overt HBV (HBsAg-positive) patients. HBsAg, anti-HBs, anti-HBc, and anti-HIV 1/2 were determined as part of routine diagnosis using Axsym assays (Abbott Laboratories, North Chicago, IL). Serum samples were PCR amplified with HBV reverse transcriptase (RT) primers, followed by direct sequencing across the tyrosine-methionine-aspartate-aspartate (YMDD) motif of the major catalytic region in the C domain of the HBV RT enzyme. HBV viral load was performed with Amplicor HBV Monitor((R)) test v2.0 (Roche Diagnostics, Penzberg, Germany). HBV lamivudine-resistant strains were detected in 3 of 15 mono-infected chronic hepatitis B patients and 10 of 20 HBV-HIV co-infected patients. To the best of our knowledge, this constitutes the first report of HBV lamivudine-resistant strains in therapy-naive HBV-HIV co-infected patients. The HBV viral loads for mono-infected and co-infected patients ranged from 3.32 x 10(2) to 3.82 x 10(7) and < 200 to 4.40 x 10(3) copies/ml, respectively. It remains to be seen whether such pre-existing antiviral mutations could result in widespread emergence of HBV resistant strains when lamivudine-containing highly active antiretroviral (ARV) treatment (HAART) regimens become widely applied in South Africa, as this is likely to have potential implications in the management of HBV-HIV co-infected patients.
引用
收藏
页码:1650 / 1654
页数:5
相关论文
共 50 条
  • [41] Anti-HBV therapy can reduce hepatitis delta replication in HIV co-infected patients
    Sheldon, Julie
    Toro, Carlos
    Ramos, Belen
    Rios, Pilar
    Martinez-Alarcon, Jose
    Romero, Miriam
    Garcia-Samaniego, Javier
    Soriano, Vicente
    HEPATOLOGY, 2007, 46 (04) : 898A - 898A
  • [42] HIV infection of chronically hepatitis B virus (HBV)-infected human hepatic and stellate cell lines: implications for pathogenesis of HIV-HBV co-infection
    Iser, D.
    Solomon, A.
    Saleh, S.
    Cornall, A.
    Warner, N.
    Cameron, P. U.
    Desmond, P. V.
    Locarnini, S. A.
    Lewin, S. R.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2008, 23 : A350 - A351
  • [43] HIV INFECTION OF CHRONICALLY HEPATITIS B VIRUS (HBV)-INFECTED HUMAN HEPATIC AND STELLATE CELL LINES: IMPLICATIONS FOR PATHOGENESIS OF HIV-HBV CO-INFECTION
    Iser, D. M.
    Solomon, A.
    Saleh, S.
    Warner, N.
    Sievert, W.
    Cameron, P. U.
    Desmond, P. V.
    Locarnini, S. A.
    Lewin, S. R.
    JOURNAL OF HEPATOLOGY, 2009, 50 : S208 - S208
  • [44] HEPATITIS B GENOTYPE DISTRIBUTION AND HIGH FREQUENCY OF LAMIVUDINE RESISTANCE MUTATIONS IN BRAZILIAN HIV/HEPATITIS B VIRUS CO-INFECTED PATIENTS
    Mendes-Correa, Maria Cossict
    Pinho, Joao R.
    Leite, Olavo M.
    Martins, Luiz G.
    Leite, Andrea G.
    Silva, Mariliza H.
    Sitnik, Roberta
    Uip, David E.
    HEPATOLOGY, 2008, 48 (04) : 538A - 538A
  • [45] EMERGENCE OF ANTIRETROVIRAL DRUG RESISTANCE IN THERAPY-NAIVE HIV INFECTED PATIENTS IN HUNGARY
    Juhasz, Emese
    Ghidan, A.
    Kemeny, B.
    Nagy, K.
    ACTA MICROBIOLOGICA ET IMMUNOLOGICA HUNGARICA, 2008, 55 (04) : 383 - 394
  • [46] Excess early mortality in HIV/hepatitis B virus co-infected patients initiating antiretroviral therapy in Kenya
    Mbae, Murithi
    Owen, Leah
    Elisha, Kirwa Kiprono
    Ndhere, Amos
    Mugambi, Ndwiga Stanley
    Yogev, Ram
    Murphy, Robert L.
    Jarvis, Joseph N.
    AIDS, 2019, 33 (08) : 1404 - 1406
  • [47] Evolution of the serologic and virologic course of occult HBV infection in therapy experienced HIV co-infected patients
    Amponsah-Dacosta, Edina
    Selabe, Selokela G.
    Mphahlele, Maphahlaganye J.
    JOURNAL OF MEDICAL VIROLOGY, 2018, 90 (02) : 291 - 303
  • [48] Fatty liver and antiretroviral therapy in HIV-positive patients co-infected with hepatitis B virus or hepatitis C virus
    Ristig, MB
    Wang, HL
    Tebas, P
    Aberg, J
    Powderly, WG
    Crippin, J
    Lisker-Melman, M
    ANTIVIRAL THERAPY, 2003, 8 (04) : L84 - L85
  • [49] The burden of liver disease in HIV/HBV co-infected patients accessing antiretroviral therapy in Ghana: the HEPIK study
    Appiah, L.
    Foster, G.
    Lepri, A. Cozzi
    Dusheiko, G.
    Bhagani, S.
    Chadwick, D.
    Philipps, R. O.
    Geretti, A-M
    Adinku, D. O.
    HIV MEDICINE, 2012, 13 : 43 - 43
  • [50] HBcAb positivity is an independent risk factor for HIV viral blips in HIV-HBV co-infected patients on antiretroviral therapy
    Malagnino, V.
    Cerva, C.
    Maffongelli, G.
    Teti, E.
    Biland, L. Foroghi
    Cesta, N.
    De Masi, M.
    Andreoni, M.
    Sarmati, L.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21